Pioneering diagnostics
E.g., 25/02/2018
E.g., 25/02/2018

Appointment of an Independent Board Member - Composition of Audit and Compensation Committees

01 October, 2004

Marcy l'Etoile, France - October 1st, 2004.

  • bioMérieux announces the nomination of a new independent Board Member, Mr Michel Angé, Vice-Président of APICIL-Prévoyance, to its Board of Directors. This nomination brings the total number of company...

bioMérieux innovates further in the fight against AIDS

27 September, 2004

Marcy l'Etoile, France - September 27th, 2004. A major player in the field of in vitro diagnostics, bioMérieux confirms its constant commitment to the fight against AIDS with the launch of two new advanced 4th generation tests for HIV screening. VIDAS® HIV DUO ULTRA and VIDAS...

VIDAS® D-Dimer Exclusion™ test from bioMérieux for reliable exclusion of pulmonary embolism and deep vein thrombosis

23 July, 2004

Marcy l'Etoile, France - July 23rd, 2004. bioMérieux announces that its D-dimer assay, VIDAS D-Dimer Exclusion, is now cleared by the U.S. Food and Drug Administration (FDA) to exclude both pulmonary embolism (PE) and deep vein thrombosis (DVT) as a diagnosis in outpatients. VIDAS D-Dimer...

Six month report January - June 2004: Sales - in line with expectations

21 July, 2004

Marcy l'Etoile, France - July 21st, 2004. bioMérieux (Euronext : FR0010096479 – BIM) today announced: During the first six months to June 2004, bioMérieux achieved sales of Euros 461 million - an increase of 3 per cent compared to the same period in 2003. The strength of the Euro,...

bioMérieux laboratories grant license to Eppendorf for One Step RT-PCR technology

13 May, 2004

Marcy l'Etoile, France - May 13, 2004. Eppendorf AG, Germany, and bioMérieux, France, have concluded a non-exclusive licensing agreement for Eppendorf products using bioMérieux's exclusively controlled One Step RT-PCR technology.

Eppendorf receives all the rights for...

VIDAS® D-Dimer Exclusion test from bioMérieux for reliable exclusion of venous thromboembolism

06 May, 2004

Marcy l'Etoile, France - May 6th, 2004. bioMérieux announces that following prospective management studies on its VIDAS D-Dimer test resulting in FDA approval and CE marking, the VIDAS D-Dimer New test has been renamed VIDAS D-Dimer Exclusion™. This name change will more accurately...

bioMérieux and South Africa, united in the fight against AIDS

04 May, 2004

Marcy l'Etoile, France - May 4th, 2004. A major player in the field of infectious disease, bioMérieux, and its exclusive distributor for South Africa, Omnimed, have just won a most important tender for the National Health Laboratory Services of South Africa as regards the fight against the...

BOOM® patent upheld in Europe

20 April, 2004

Marcy l'Etoile, France - April 20th, 2004. The European Patent Office’s Board of Appeal has found in favour of bioMérieux in the opposition to its European patent for the Boom technology.

European Patent No. 0,389,063 granted in 1997 is owned by bioMérieux further to the...

NucliSens®, miniMAG™, the first product from bioMérieux’s next generation nucleic acid extraction platform now available.

02 April, 2004

Marcy l'Etoile, France - April 2nd, 2004. bioMérieux announces the introduction of NucliSens miniMAG and NucliSens Magnetic Extraction Reagents, two key components of the company’s next generation nucleic acid extraction technology.

“These two products make up a novel...

U.S. FDA Premarket Notification 510(k) Clearance of Polycarbonate BacT/ALERT® Culture Bottles for Microbial QC Testing of Leukocyte-Reduced Single Units of Whole Blood Platelet Concentrates (WBPC)

26 March, 2004

Marcy-l’Etoile, France - March 26, 2004. bioMérieux announces U.S. FDA-CBER (1) Premarket Notification 510(k) clearance of the recently launched, innovative polycarbonate BacT/ALERT BPA and BacT/ALERT BPN culture bottles for microbial quality control testing of leukocyte-reduced single...